{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:51:46Z","timestamp":1790419906993,"version":"4.1.0"},"reference-count":42,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Konkuk University"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal malignancies due to late diagnosis, poor drug penetration, and intrinsic chemoresistance. Targeted delivery strategies are urgently needed to enhance therapeutic precision while minimizing systemic toxicity. Here, we developed an AS1411 aptamer-functionalized liposomal platform encapsulating siRNA against metastasis-associated protein 2 (MTA2), a chromatin remodeling factor that suppresses the tumor suppressor PTEN and activates PI3K\/AKT signaling. The AS1411 aptamer, which binds nucleolin overexpressed on PDAC cells, was conjugated to cationic liposomes via copper-free click chemistry. The resulting AS1411-Lipm[siRNA] exhibited high siRNA encapsulation efficiency, selective uptake by nucleolin-positive PDAC cells, and enhanced endosomal escape. Treatment of MIA PaCa-2 cells with AS1411-Lipm[siRNA] significantly reduced MTA2 expression by ~60%, substantially restored PTEN, and inhibited AKT phosphorylation by ~50%, leading to decreased cell viability, impaired migration by ~75%, and increased apoptosis by ~35%, while sparing nucleolin-negative cells. These findings highlight AS1411-Lipm[siRNA] as a promising platform for selective siRNA delivery and potent molecular inhibition in PDAC therapy.<\/jats:p>","DOI":"10.3390\/ijms26178467","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T15:02:57Z","timestamp":1756825377000},"page":"8467","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["AS1411 Aptamer-Conjugated Liposomal siRNA Targeting MTA2 Suppresses PI3K\/AKT Signaling in Pancreatic Cancer Cells"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7683-819X","authenticated-orcid":false,"given":"Minseo","family":"Kwak","sequence":"first","affiliation":[{"name":"Department of Bioscience and Biotechnology, Konkuk University, Seoul 05029, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8228-1077","authenticated-orcid":false,"given":"Truong Chinh","family":"Hua","sequence":"additional","affiliation":[{"name":"Department of Bioscience and Biotechnology, Konkuk University, Seoul 05029, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3252-6099","authenticated-orcid":false,"given":"Hyesoo","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Bioscience and Biotechnology, Konkuk University, Seoul 05029, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6266-3983","authenticated-orcid":false,"given":"Jongsam","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Bioscience and Biotechnology, Konkuk University, Seoul 05029, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6545-8387","authenticated-orcid":false,"given":"Dong-Eun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Bioscience and Biotechnology, Konkuk University, Seoul 05029, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nrm3330","article-title":"The functions and regulation of the PTEN tumour suppressor","volume":"13","author":"Song","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K Pathway in Human Disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Mehra, S., Deshpande, N., and Nagathihalli, N. (2021). Targeting PI3K Pathway in Pancreatic Ductal Adenocarcinoma: Rationale and Progress. Cancers, 13.","DOI":"10.3390\/cancers13174434"},{"key":"ref_4","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","article-title":"Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes","volume":"24","author":"McGuigan","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41571-023-00746-1","article-title":"Neoadjuvant therapy for pancreatic cancer","volume":"20","author":"Springfeld","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"688377","DOI":"10.3389\/fonc.2021.688377","article-title":"The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy","volume":"11","author":"Principe","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"571","DOI":"10.4251\/wjgo.v15.i4.571","article-title":"Recent advances in targeted therapy for pancreatic adenocarcinoma","volume":"15","author":"Fang","year":"2023","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nrc2966","article-title":"RNA interference in the clinic: Challenges and future directions","volume":"11","author":"Pecot","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"644718","DOI":"10.3389\/fphar.2021.644718","article-title":"Insight Into the Prospects for RNAi Therapy of Cancer","volume":"12","author":"Tian","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nmat3765","article-title":"Delivery materials for siRNA therapeutics","volume":"12","author":"Kanasty","year":"2013","journal-title":"Nat. Mater."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Kim, M.J., Chang, H., Nam, G., Ko, Y., Kim, S.H., Roberts, T.M., and Ryu, J.H. (2021). RNAi-Based Approaches for Pancreatic Cancer Therapy. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13101638"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41419-019-1424-5","article-title":"MTA2-mediated inhibition of PTEN leads to pancreatic ductal adenocarcinoma carcinogenicity","volume":"10","author":"Si","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s13277-013-0685-3","article-title":"MTA2 expression is a novel prognostic marker for pancreatic ductal adenocarcinoma","volume":"34","author":"Chen","year":"2013","journal-title":"Tumour Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.addr.2016.06.011","article-title":"Recent progress in development of siRNA delivery vehicles for cancer therapy","volume":"104","author":"Kim","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nbt.3802","article-title":"Overcoming cellular barriers for RNA therapeutics","volume":"35","author":"Dowdy","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: From concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nbt.1602","article-title":"Rational design of cationic lipids for siRNA delivery","volume":"28","author":"Semple","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jconrel.2010.03.016","article-title":"Stealth nanoparticles: High density but sheddable PEG is a key for tumor targeting","volume":"145","author":"Li","year":"2010","journal-title":"J. Control Release"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ejpb.2008.09.026","article-title":"Multifunctional and stimuli-sensitive pharmaceutical nanocarriers","volume":"71","author":"Torchilin","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/j.bpj.2016.03.040","article-title":"Interstitial Pressure in Pancreatic Ductal Adenocarcinoma Is Dominated by a Gel-Fluid Phase","volume":"110","author":"DuFort","year":"2016","journal-title":"Biophys. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1146\/annurev-chembioeng-061010-114300","article-title":"Delivery of molecular and nanoscale medicine to tumors: Transport barriers and strategies","volume":"2","author":"Chauhan","year":"2011","journal-title":"Annu. Rev. Chem. Biomol. Eng."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2013.11.009","article-title":"Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology","volume":"66","author":"Bertrand","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrd3141","article-title":"Aptamers as therapeutics","volume":"9","author":"Keefe","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s40291-018-0338-8","article-title":"Current Transport Systems and Clinical Applications for Small Interfering RNA (siRNA) Drugs","volume":"22","author":"Liu","year":"2018","journal-title":"Mol. Diagn. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.yexmp.2009.01.004","article-title":"Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer","volume":"86","author":"Bates","year":"2009","journal-title":"Exp. Mol. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"8617","DOI":"10.1158\/0008-5472.CAN-10-0920","article-title":"A new paradigm for aptamer therapeutic AS1411 action: Uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism","volume":"70","author":"Teng","year":"2010","journal-title":"Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.msec.2016.11.053","article-title":"Study and evaluation of nucleolin-targeted delivery of magnetic PLGA-PEG nanospheres loaded with doxorubicin to C6 glioma cells compared with low nucleolin-expressing L929 cells","volume":"72","author":"Mosafer","year":"2017","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"key":"ref_32","first-page":"146","article-title":"AS1411-functionalized delivery nanosystems for targeted cancer therapy","volume":"2","author":"Kozani","year":"2021","journal-title":"Explor. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jconrel.2014.10.018","article-title":"RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo","volume":"196","author":"Baek","year":"2014","journal-title":"J. Control Release"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1021\/acsabm.9b00705","article-title":"Anti-MUC1\/CD44 Dual-Aptamer-Conjugated Liposomes for Cotargeting Breast Cancer Cells and Cancer Stem Cells","volume":"2","author":"Kim","year":"2019","journal-title":"ACS Appl. Bio Mater."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jconrel.2022.06.039","article-title":"Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression","volume":"348","author":"Kim","year":"2022","journal-title":"J. Control Release"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.omtn.2018.06.003","article-title":"Gemcitabine-Incorporated G-Quadruplex Aptamer for Targeted Drug Delivery into Pancreas Cancer","volume":"12","author":"Park","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_37","first-page":"265","article-title":"A DNA aptamer recognizing MMP14 for in vivo and in vitro imaging identified by cell-SELEX","volume":"18","author":"Huang","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"985","DOI":"10.7150\/thno.11938","article-title":"DNA Aptamer Selected against Pancreatic Ductal Adenocarcinoma for in vivo Imaging and Clinical Tissue Recognition","volume":"5","author":"Wu","year":"2015","journal-title":"Theranostics"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1089\/nat.2016.0621","article-title":"A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma","volume":"27","author":"Clawson","year":"2017","journal-title":"Nucleic Acid. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.omtn.2017.12.021","article-title":"STAT3 Gene Silencing by Aptamer-siRNA Chimera as Selective Therapeutic for Glioblastoma","volume":"10","author":"Esposito","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"7928","DOI":"10.1021\/acsnano.4c14969","article-title":"siRNA-Encapsulated Biomimetic Liposomes Effectively Inhibit Tumor Cells\u2019 Hexosamine Biosynthesis Pathway for Attenuating Hyaluronan Barriers to Pancreatic Cancer Chemotherapy","volume":"19","author":"Wu","year":"2025","journal-title":"ACS Nano"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jconrel.2017.12.022","article-title":"Aptamer-guided siRNA-loaded nanomedicines for systemic gene silencing in CD-44 expressing murine triple-negative breast cancer model","volume":"271","author":"Alshaer","year":"2018","journal-title":"J. Control Release"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/17\/8467\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:36:21Z","timestamp":1760034981000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/17\/8467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,30]]},"references-count":42,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["ijms26178467"],"URL":"https:\/\/doi.org\/10.3390\/ijms26178467","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,30]]}}}